Syndax Pharmaceuticals: Guggenheim Sees Undervaluation with 111% Price Potential!
Reading Time: 2 minutes
Syndax Pharmaceuticals (SNDX) published its Q2 report on August 4, 2025. According to the report, it reported revenue of $37.956 million and an EPS of -$0.83. Growth drivers included Revuforj (revumenib) and Niktimvo (axatilimab-csfr). For example, Revuforj's net product revenue increased by 43% compared to Q1. Revuforj was approved in the U.S. in November 2024 for the treatment of relapsed or refractory acute leukemia (R/R AML) with a KMT2A translocation. Another growth driver for Revuforj is the upcoming approval as the first therapy for R/R mNPM1...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
